Cardiac carnitine leakage is promoted by cardiomyopathy

Baker, Herman; DeAngelis, Barbara; Orlando, James; Correia, Joaquin

doi:10.1016/j.nut.2004.07.009

Cited by 3 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A series of studies clearly demonstrates that during the development of experimental 34 and clinical 35 cardiac damage there is a release of free 36 and acyl-carnitines from the heart that increase plasma concentrations 29,37 and urinary excretion. 37 Conflicting results on the relationship between plasma levels and heart failure severity measured by the NYHA classification 29 have been obtained.…”

Section: Discussionmentioning

confidence: 99%

Effect of intravenous l-carnitine in Chinese patients with chronic heart failure

Jing

Peng

et al. 2016

Eur Heart J Suppl

View full text Add to dashboard Cite

Chronic heart failure (CHF) may be associated with an energy deficit in cardiac muscle. As levo-carnitine (LC) is involved in the production of myocardial energy, it is hypothesized that LC supplementation may ameliorate CHF symptoms. This multicentre, randomized, double-blind, and placebo-controlled study included 265 patients with CHF. Patients were randomized to receive either LC or placebo, twice a day. Endpoints were measured after 7 days of treatment. Primary endpoint was a reduction of at least one NYHA class. Secondary endpoints were changes in 6-min walk distance (6-MWD) compared with baseline, either alone or in combination with NYHA class decrease, left ventricular ejection fraction, and NT-proBNP level, together with adverse events. The primary endpoint was reached in 60.9% of patients treated with LC, compared with only 44.7% of the placebo group (P ¼ 0.012). Among the secondary endpoints, 6-MWD, alone or in combination with NYHA class, improved significantly in the LC group compared with placebo (P ¼ 0.0497 and P ¼ 0.003, respectively). values of plasma-free carnitine were observed in patients with NYHA classes III and IV where the effect of LC supplementation was greatest (P ¼ 0.002). Treatment with LC significantly improved CHF symptoms in Chinese patients, probably by correcting a status of carnitine insufficiency.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of intravenous l-carnitine in Chinese patients with chronic heart failure

Jing

Peng

et al. 2016

Eur Heart J Suppl

View full text Add to dashboard Cite

show abstract

Efficacy of L-Carnitine for Dilated Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials

Weng

Zhang

Huang

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

Background. L-carnitine mediates the utilization of fatty acids and glucose in the myocardium. The potential of L-carnitine in managing dilated cardiomyopathy (DCM) in patients has been extensively reported, with additional benefits. Objective. This meta-analysis purposed to explore the clinical efficacy of L-carnitine therapy on DCM patients. Methods. We searched publications up to May 2020 from several databases including PubMed, Embase, Cochrane Library, Chinese Biomedical (CBM) database, Chinese Science and Technology Periodicals database (VIP), Chinese National Knowledge Infrastructure (CNKI) database, and Wanfang database. Subsequently, publications that met the inclusion criteria were systematically evaluated by two independent reviewers. Results. A total of 23 RCTs conducted in China with 1455 DCM patients were included in this study. In the meta-analysis, L-carnitine therapy was associated with a considerable improvement in the overall efficacy ( RR = 1.28 , 95% CI (1.21-1.36), P < 0.0001 ), left ventricular ejection fraction (LVEF) ( MD = 6.16 % , 95% CI (4.50, 7.83), P < 0.0001 ), and cardiac output (CO) ( MD = 0.88 L/min, 95% CI (0.51, 1.25), P < 0.0001 ) as compared to the control group. Moreover, L-carnitine therapy significantly decreased left ventricular end-diastolic dimension (LVEDD) ( MD = − 2.53 , 95% CI (-3.95, -1.12), P = 0.0005 ), brain natriuretic peptide (BNP) ( SMD = − 1.71 ng/L, 95% CI (-3.02, -0.40), P = 0.01 ), and the transforming growth factor-beta (TGF-β1) ( MD = − 56.78 ng/L, 95% CI (-66.02, -47.53), P < 0.0001 ). Conclusions. L-carnitine potentially enhanced the therapeutic efficiency in DCM patients. Following weaknesses in the evidence due to low methodological quality and high clinical heterogeneity in the included studies, well-designed trials are recommended.

show abstract

Therapeutic Evaluation of L-Carnitine in Egyptian Children with Dilated Cardiomyopathy

Kotby¹,

Yamamah²,

Baky³

et al. 2006

J. of Medical Sciences

View full text Add to dashboard Cite

Cardiac carnitine leakage is promoted by cardiomyopathy

Cited by 3 publications

References 19 publications

Effect of intravenous l-carnitine in Chinese patients with chronic heart failure

Effect of intravenous l-carnitine in Chinese patients with chronic heart failure

Efficacy of L-Carnitine for Dilated Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials

Therapeutic Evaluation of L-Carnitine in Egyptian Children with Dilated Cardiomyopathy

Contact Info

Product

Resources

About